Natera, Inc.
Natera, Inc. (NTRA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NTRA · as of Jun 8, 2026
Key Statistics
Explore Natera, Inc. Data
ntra stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 27 · Buy rate: 88.9%
The NTRA analyst consensus is Buy, based on ratings from 27 Wall Street analysts over the past 3 months. The average 12-month price target is $259.25, representing +19.20% upside from the current price of $217.50.
Competitors & Peers
ntra competitorsNTRA
BNTX
DGX
DXCM
ILMN
IQVStock Performance
Full HistoryAbout Natera, Inc.
Natera, Inc. a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a …
what is natera, inc. · ntra stock overview · natera, inc. company profile · who is natera, inc. ceo · ntra NASDAQ · natera, inc. headquarters · natera, inc. business segments
About Stock Overview & Key Data
Natera, Inc. (NTRA) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on NASDAQ since Jul 1, 2015. As of the latest trading session, NTRA stock price is $217.50, with a market capitalization of $31.0B. The stock has returned +31.13% over the past 12 months and -6.02% year-to-date.
According to 27 Wall Street analysts, the consensus rating for Natera, Inc. stock is Buy, with an average 12-month price target of $259.25. In fiscal year 2025, Natera, Inc. reported revenue of $2.3B and net income of -$208.2M. For detailed data — including Natera, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Natera, Inc. (NTRA) stock price is $217.50. The stock is traded on NASDAQ under the ticker symbol NTRA. The 52-week range is $131.81 – $256.36.